<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02942680</url>
  </required_header>
  <id_info>
    <org_study_id>1184</org_study_id>
    <nct_id>NCT02942680</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aspirin Therapy With CABG</brief_title>
  <official_title>A Prospective Randomized Study of the Efficacy and Safety of Aspirin Therapy With CABG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the safety of preoperative aspirin therapy when performing bypass surgery in
      conditions of artificial blood circulation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of the study was that aspirin therapy started 24 hours before CABG is safe.

      The effectiveness of this hypothesis will be assessed by the presence of a 30-day period
      after CABG myocardial infarction, ischemic stroke, repeat revascularizations
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>on discharge drains after surgery in milliliters</measure>
    <time_frame>24 hours after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>myocardial infarction</measure>
    <time_frame>myocardial infarction by 30th day after procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic stroke</measure>
    <time_frame>stroke by 30th day after procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>repeat revascularization</measure>
    <time_frame>repeat revascularization within 30 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>acetylsalicylic acid started for 24 hours before surgery and determination of platelet function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>acetylsalicylic acid stayed for 5 days before surgery and determination of platelet function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid started for 24 hours before surgery</intervention_name>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid stayed for 5 days before surgery</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years of age or older

          -  Patient able to give informed consent

        Exclusion Criteria:

          -  Missing consent

          -  Urgent or emergent surgery

          -  Off-pump CABG

          -  Ð atient has clear indication for anticoagulation (eg. mechanical heart valve, atrial
             fibrillation) or ADP receptor antagonist (eg. drug-eluting stent)

          -  History of bleeding diathesis, significant GI bleed, ICH, or liver failure

          -  Allergy to or intolerance of aspirin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander M. Chernyavskiy, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Academician Ye. Meshalkin Novosibirsk Research Institute of Circulation Pathology Ministry of Health care of Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aleksey Kurguzov</last_name>
    <phone>+9137011917</phone>
    <email>Aleksey_kurguzov@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>Meshalkin State Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aleksey kurguzov</last_name>
      <phone>+79137011917</phone>
      <email>aleksey_kurguzov@mail.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 21, 2016</last_update_submitted>
  <last_update_submitted_qc>October 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery bypass grafting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

